Patents by Inventor Paula M. Jardieu
Paula M. Jardieu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20020054878Abstract: The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.Type: ApplicationFiled: August 1, 2001Publication date: May 9, 2002Applicant: Genentech, Inc.Inventors: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
-
Patent number: 6329509Abstract: Two classes of polypeptides derived from human IgE are described. One class binds selectively to the high affinity IgE receptor on mast cells and basophils, but not to the low affinity IgE receptor on B-cells, monocytes, eosinophils and platelets. The other class binds to the low affinity receptor, but not the high affinity receptor. The differential binding polypeptides of this invention are useful in diagnostic procedures for IgE receptors or in the therapy of IgE-mediated disorders such as allergies. They also are useful in preparing antibodies capable of binding regions of IgE that participate in receptor binding.Type: GrantFiled: June 6, 1995Date of Patent: December 11, 2001Assignee: Genentech, Inc.Inventors: Paula M. Jardieu, Leonard G. Presta
-
Publication number: 20010038839Abstract: The present invention describes IgE antagonists (including variant anti-IgE antibodies) and their use in diagnosis, therapy or prophylaxis of allergic and other IgE-mediated disorders, including asthma, food allergies, hypersensitivity and anaphylactic reactions.Type: ApplicationFiled: March 8, 2001Publication date: November 8, 2001Applicant: Genentech, Inc.Inventors: Paula M. Jardieu, Leonard G. Presta
-
Publication number: 20010033842Abstract: The present invention describes IgE antagonists (including variant anti-IgE antibodies) and their use in diagnosis, therapy or prophylaxis of allergic and other IgE-mediated disorders, including asthma, food allergies, hypersensitivity and anaphylactic reactions.Type: ApplicationFiled: March 8, 2001Publication date: October 25, 2001Applicant: Genentech, Inc.Inventors: Paula M. Jardieu, Leonard G. Presta
-
Patent number: 6290957Abstract: The present invention relates to a method for adjusting the affuinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.Type: GrantFiled: April 21, 1999Date of Patent: September 18, 2001Inventors: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
-
Patent number: 6172213Abstract: The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of substituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.Type: GrantFiled: June 30, 1998Date of Patent: January 9, 2001Assignee: Genentech, Inc.Inventors: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
-
Patent number: 6037454Abstract: Humanized anti-CD11a antibodies and various uses therefor are disclosed. The humanized anti-CD11a antibody may bind specifically to human CD11a I-domain, have an IC50(nM) value of no more than about 1 nM for preventing adhesion of Jurkat cells to normal human epidermal keratinocytes expressing ICAM-1, and/or an IC50 (nM) value of no more than about 1 nM in the mixed lymphocyte response assay.Type: GrantFiled: November 20, 1997Date of Patent: March 14, 2000Assignee: Genentech, Inc.Inventors: Paula M. Jardieu, Leonard G. Presta
-
Patent number: 6037453Abstract: Two classes of polypeptides derived from human IgE are described. One class binds selectively to the high affinity IgE receptor on mast cells and basophils, but not to the low affinity IgE receptor on B-cells, monocytes, eosinophils and platelets. The other class binds to the low affinity receptor, but not the high affinity receptor. The differential binding polypeptides of this invention are useful in diagnostic procedures for IgE receptors or in the therapy of IgE-mediated disorders such as allergies. They also are useful in preparing antibodies capable of binding regions of IgE that participate in receptor binding.Type: GrantFiled: June 6, 1995Date of Patent: March 14, 2000Assignee: Genentech, Inc.Inventors: Paula M. Jardieu, Leonard G. Presta
-
Patent number: 5994511Abstract: The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.Type: GrantFiled: July 2, 1997Date of Patent: November 30, 1999Assignee: Genentech, Inc.Inventors: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
-
Patent number: 5994514Abstract: Two classes of polypeptides derived from human IgE are described. One class binds selectively to the high affinity IgE receptor on mast cells and basophils, but not to the low affinity IgE receptor on B-cells, monocytes, eosinophils and platelets. The other class binds to the low affinity receptor, but not the high affinity receptor. The differential binding polypeptides of this invention are useful in diagnostic procedures for IgE receptors or in the therapy of IgE-mediated disorders such as allergies. They also are useful in preparing antibodies capable of binding regions of IgE that participate in receptor binding.Type: GrantFiled: June 5, 1995Date of Patent: November 30, 1999Assignee: Genentech, Inc.Inventors: Paula M. Jardieu, Leonard G. Presta
-
Patent number: 5965709Abstract: IgE antagonists comprising one or more of the Fc.sub..epsilon. RI receptor-binding determinant sites of human IgE are described. The disclosed antagonists include IgE variants, peptide antagonists, peptidomimetics and other small molecules. The antagonists are useful in raising and screening anti-IgE antibodies, in the isolation and purification of Fc.sub..epsilon. RI receptor, and in the treatment of allergic disease.Type: GrantFiled: April 21, 1994Date of Patent: October 12, 1999Assignee: Genentech, Inc.Inventors: Leonard G. Presta, Paula M. Jardieu
-
Patent number: 5656273Abstract: This invention concerns a method for the prevention and treatment of parasitic infection by administering an IgE antagonists. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method.Type: GrantFiled: April 14, 1995Date of Patent: August 12, 1997Assignee: Genentech, Inc.Inventors: Payman Amiri, Mary Haak-Frendscho, Paula M. Jardieu
-
Patent number: 5622700Abstract: A method is provided for administering to a mammal suffering from, or at risk for, a LFA-1-mediated disorder an initial dosing of a therapeutically effective amount of LFA-1 antagonist, followed by a subsequent intermittent dosing of a therapeutically effective amount of LFA-1 antagonist that is less than 100%, calculated on a daily basis, of the initial dosing of antagonist.Type: GrantFiled: May 2, 1995Date of Patent: April 22, 1997Assignee: Genentech, Inc.Inventors: Paula M. Jardieu, Bruce Montgomery
-
Patent number: 5583109Abstract: A method is disclosed for stimulating a mammal's or avian's immune response, particularly immune-compromised mammals, by administration of IGF-I, alone or in combination with growth hormone. Preferably, the IGF-I is native-sequence, mature human IGF-I.Type: GrantFiled: March 13, 1995Date of Patent: December 10, 1996Assignees: Genentech, Inc., University of Tennessee ResearchInventors: Ross G. Clark, Paula M. Jardieu, Kenneth A. Kudsk
-
Patent number: 5227158Abstract: The invention relates to the synergistic interaction of hepatocyte growth factor (HGF) and gamma-interferon (IFN-.gamma.) in the stimulation of hepatocyte growth. Accordingly, the invention concerns a method of enhancing the biological activity of HGF by administering a biologically effective amount of HGF and a synergistically effective amount of IFN-.gamma. to a patient in need.Type: GrantFiled: June 10, 1991Date of Patent: July 13, 1993Assignee: Genentech, Inc.Inventor: Paula M. Jardieu
-
Patent number: 5202119Abstract: A method is disclosed for stimulating a mammal's or avian's immune response, particularly immune-compromised mammals, by administration of IGF-I, alone or in combination with growth hormone. Preferably, the IGF-I is native-sequence, mature human IGF-I.Type: GrantFiled: June 28, 1991Date of Patent: April 13, 1993Assignee: Genentech, Inc.Inventors: Ross G. Clark, Paula M. Jardieu
-
Patent number: 5196191Abstract: Methods for the treatment of allergic reactions are provided, wherein a pharmaceutically effective dose of gamma interferon is administered to a patient within a predetermined temporal period prior to or following exposure to an allergen.Type: GrantFiled: October 10, 1991Date of Patent: March 23, 1993Assignee: Genentech, Inc.Inventor: Paula M. Jardieu